Author:
Li Ma-chao,Lu Yao,Liu Hai-can,Lin Shi-qiang,Qian Cheng,Nan Xiao-tian,Li Gui-lian,Zhao Xiu-qin,Wan Kang-Lin,Zhao Li-li
Funder
National Key Program of Mega Infectious Diseases
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology
Reference19 articles.
1. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. licence: cc bY-Nc-sa 3.0 iGo.
2. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
3. Chien JY, Chiu WY, Chien ST, Chiang CJ, Yu CJ, Hsueh PR. Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother. 2016;60:2090–6.
4. Willby M, Sikes RD, Malik S, Metchock B, Posey JE. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:5427–34.
5. Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J, Rodwell T. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One. 2015;10:e0120470.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献